GB0908613D0 - T Cell Reseptors - Google Patents

T Cell Reseptors

Info

Publication number
GB0908613D0
GB0908613D0 GBGB0908613.3A GB0908613A GB0908613D0 GB 0908613 D0 GB0908613 D0 GB 0908613D0 GB 0908613 A GB0908613 A GB 0908613A GB 0908613 D0 GB0908613 D0 GB 0908613D0
Authority
GB
United Kingdom
Prior art keywords
reseptors
cell
cell reseptors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0908613.3A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunocore Ltd
Original Assignee
Immunocore Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40834242&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB0908613(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunocore Ltd filed Critical Immunocore Ltd
Priority to GBGB0908613.3A priority Critical patent/GB0908613D0/en
Publication of GB0908613D0 publication Critical patent/GB0908613D0/en
Priority to DK10720803.5T priority patent/DK2432802T3/en
Priority to ES10720803.5T priority patent/ES2608653T3/en
Priority to EP10720803.5A priority patent/EP2432802B1/en
Priority to SI201031358A priority patent/SI2432802T1/en
Priority to SI201031697T priority patent/SI3112377T1/en
Priority to US13/319,597 priority patent/US10130721B2/en
Priority to CA2762604A priority patent/CA2762604C/en
Priority to CA2968393A priority patent/CA2968393C/en
Priority to SM20190232T priority patent/SMT201900232T1/en
Priority to EP16176249.7A priority patent/EP3112377B1/en
Priority to HUE16176246A priority patent/HUE043245T2/en
Priority to SM20170067T priority patent/SMT201700067T1/en
Priority to SI201031883T priority patent/SI3112376T1/en
Priority to HRP20170086TT priority patent/HRP20170086T1/en
Priority to HUE16176249A priority patent/HUE038342T2/en
Priority to TR2019/05437T priority patent/TR201905437T4/en
Priority to CN201080022523.6A priority patent/CN102439034B/en
Priority to BRPI1013029A priority patent/BRPI1013029A2/en
Priority to ES16176246T priority patent/ES2721058T3/en
Priority to LTEP16176246.3T priority patent/LT3112376T/en
Priority to DK16176249.7T priority patent/DK3112377T3/en
Priority to HUE10720803A priority patent/HUE032929T2/en
Priority to PT161762497T priority patent/PT3112377T/en
Priority to AU2010250951A priority patent/AU2010250951B2/en
Priority to JP2012511333A priority patent/JP5667171B2/en
Priority to MX2011012184A priority patent/MX340168B/en
Priority to LTEP10720803.5T priority patent/LT2432802T/en
Priority to EA201101660A priority patent/EA020841B1/en
Priority to SM20180364T priority patent/SMT201800364T1/en
Priority to ES16176249.7T priority patent/ES2672095T3/en
Priority to DK16176246.3T priority patent/DK3112376T3/en
Priority to TR2018/09945T priority patent/TR201809945T4/en
Priority to PL10720803T priority patent/PL2432802T3/en
Priority to PL16176246T priority patent/PL3112376T3/en
Priority to PL16176249T priority patent/PL3112377T3/en
Priority to PT16176246T priority patent/PT3112376T/en
Priority to EP16176246.3A priority patent/EP3112376B1/en
Priority to LTEP16176249.7T priority patent/LT3112377T/en
Priority to PT107208035T priority patent/PT2432802T/en
Priority to PCT/GB2010/000988 priority patent/WO2010133828A1/en
Priority to JP2014250885A priority patent/JP2015096527A/en
Priority to CY20161101365T priority patent/CY1118405T1/en
Priority to JP2017009529A priority patent/JP2017110019A/en
Priority to CY20181100507T priority patent/CY1120439T1/en
Priority to HRP20180757TT priority patent/HRP20180757T1/en
Priority to US16/151,144 priority patent/US20190247512A1/en
Priority to US16/378,501 priority patent/US10576162B2/en
Priority to US16/378,505 priority patent/US10420846B2/en
Priority to US16/378,481 priority patent/US10517960B2/en
Priority to HRP20190674TT priority patent/HRP20190674T1/en
Priority to CY20191100410T priority patent/CY1121558T1/en
Priority to JP2019088405A priority patent/JP2019172678A/en
Priority to US17/929,682 priority patent/US20230241238A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/00114—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
GBGB0908613.3A 2009-05-20 2009-05-20 T Cell Reseptors Ceased GB0908613D0 (en)

Priority Applications (54)

Application Number Priority Date Filing Date Title
GBGB0908613.3A GB0908613D0 (en) 2009-05-20 2009-05-20 T Cell Reseptors
DK10720803.5T DK2432802T3 (en) 2009-05-20 2010-05-19 Bifunctional polypeptides
ES10720803.5T ES2608653T3 (en) 2009-05-20 2010-05-19 Bifunctional polypeptides
EP10720803.5A EP2432802B1 (en) 2009-05-20 2010-05-19 Bifunctional polypeptides
SI201031358A SI2432802T1 (en) 2009-05-20 2010-05-19 Bifunctional polypeptides
SI201031697T SI3112377T1 (en) 2009-05-20 2010-05-19 Bifunctional polypeptides
US13/319,597 US10130721B2 (en) 2009-05-20 2010-05-19 Bifunctional polypeptides
CA2762604A CA2762604C (en) 2009-05-20 2010-05-19 Bifunctional polypeptides
CA2968393A CA2968393C (en) 2009-05-20 2010-05-19 Bifunctional polypeptides
SM20190232T SMT201900232T1 (en) 2009-05-20 2010-05-19 Bifunctional polypeptides
EP16176249.7A EP3112377B1 (en) 2009-05-20 2010-05-19 Bifunctional polypeptides
HUE16176246A HUE043245T2 (en) 2009-05-20 2010-05-19 Bifunctional polypeptides
SM20170067T SMT201700067T1 (en) 2009-05-20 2010-05-19 Bifunctional polypeptides
SI201031883T SI3112376T1 (en) 2009-05-20 2010-05-19 Bifunctional polypeptides
HRP20170086TT HRP20170086T1 (en) 2009-05-20 2010-05-19 Bifunctional polypeptides
HUE16176249A HUE038342T2 (en) 2009-05-20 2010-05-19 Bifunctional polypeptides
TR2019/05437T TR201905437T4 (en) 2009-05-20 2010-05-19 Bifunctional polypeptides.
CN201080022523.6A CN102439034B (en) 2009-05-20 2010-05-19 Bifunctional polypeptides
BRPI1013029A BRPI1013029A2 (en) 2009-05-20 2010-05-19 bifunctional polypeptides
ES16176246T ES2721058T3 (en) 2009-05-20 2010-05-19 Bifunctional polypeptides
LTEP16176246.3T LT3112376T (en) 2009-05-20 2010-05-19 Bifunctional polypeptides
DK16176249.7T DK3112377T3 (en) 2009-05-20 2010-05-19 BIFUNCTIONAL POLYPEPTIDES
HUE10720803A HUE032929T2 (en) 2009-05-20 2010-05-19 Bifunctional polypeptides
PT161762497T PT3112377T (en) 2009-05-20 2010-05-19 Bifunctional polypeptides
AU2010250951A AU2010250951B2 (en) 2009-05-20 2010-05-19 Bifunctional polypeptides
JP2012511333A JP5667171B2 (en) 2009-05-20 2010-05-19 Bifunctional polypeptide
MX2011012184A MX340168B (en) 2009-05-20 2010-05-19 Bifunctional polypeptides.
LTEP10720803.5T LT2432802T (en) 2009-05-20 2010-05-19 Bifunctional polypeptides
EA201101660A EA020841B1 (en) 2009-05-20 2010-05-19 Bifunctional polypeptides
SM20180364T SMT201800364T1 (en) 2009-05-20 2010-05-19 Bifunctional polypeptides
ES16176249.7T ES2672095T3 (en) 2009-05-20 2010-05-19 Bifunctional polypeptides
DK16176246.3T DK3112376T3 (en) 2009-05-20 2010-05-19 BIFUNCTIONAL POLYPEPTIDES
TR2018/09945T TR201809945T4 (en) 2009-05-20 2010-05-19 Bifunctional polypeptides.
PL10720803T PL2432802T3 (en) 2009-05-20 2010-05-19 Bifunctional polypeptides
PL16176246T PL3112376T3 (en) 2009-05-20 2010-05-19 Bifunctional polypeptides
PL16176249T PL3112377T3 (en) 2009-05-20 2010-05-19 Bifunctional polypeptides
PT16176246T PT3112376T (en) 2009-05-20 2010-05-19 Bifunctional polypeptides
EP16176246.3A EP3112376B1 (en) 2009-05-20 2010-05-19 Bifunctional polypeptides
LTEP16176249.7T LT3112377T (en) 2009-05-20 2010-05-19 Bifunctional polypeptides
PT107208035T PT2432802T (en) 2009-05-20 2010-05-19 Bifunctional polypeptides
PCT/GB2010/000988 WO2010133828A1 (en) 2009-05-20 2010-05-19 Bifunctional polypeptides
JP2014250885A JP2015096527A (en) 2009-05-20 2014-12-11 Bifunctional polypeptides
CY20161101365T CY1118405T1 (en) 2009-05-20 2016-12-30 BUSINESS INTERFACE polypeptides
JP2017009529A JP2017110019A (en) 2009-05-20 2017-01-23 Bifunctional polypeptide
CY20181100507T CY1120439T1 (en) 2009-05-20 2018-05-04 BUSINESS INTERFACE polypeptides
HRP20180757TT HRP20180757T1 (en) 2009-05-20 2018-05-15 Bifunctional polypeptides
US16/151,144 US20190247512A1 (en) 2009-05-20 2018-10-03 Bifunctional polypeptides
US16/378,501 US10576162B2 (en) 2009-05-20 2019-04-08 Bifunctional polypeptides
US16/378,505 US10420846B2 (en) 2009-05-20 2019-04-08 Bifunctional polypeptides
US16/378,481 US10517960B2 (en) 2009-05-20 2019-04-08 Bifunctional polypeptides
HRP20190674TT HRP20190674T1 (en) 2009-05-20 2019-04-09 Bifunctional polypeptides
CY20191100410T CY1121558T1 (en) 2009-05-20 2019-04-12 DIFFERENTIAL POLYPEPTIDES
JP2019088405A JP2019172678A (en) 2009-05-20 2019-05-08 Bifunctional polypeptides
US17/929,682 US20230241238A1 (en) 2009-05-20 2022-09-02 Bifunctional polypeptides

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0908613.3A GB0908613D0 (en) 2009-05-20 2009-05-20 T Cell Reseptors

Publications (1)

Publication Number Publication Date
GB0908613D0 true GB0908613D0 (en) 2009-06-24

Family

ID=40834242

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0908613.3A Ceased GB0908613D0 (en) 2009-05-20 2009-05-20 T Cell Reseptors

Country Status (22)

Country Link
US (6) US10130721B2 (en)
EP (3) EP3112376B1 (en)
JP (4) JP5667171B2 (en)
CN (1) CN102439034B (en)
AU (1) AU2010250951B2 (en)
BR (1) BRPI1013029A2 (en)
CA (2) CA2762604C (en)
CY (3) CY1118405T1 (en)
DK (3) DK2432802T3 (en)
EA (1) EA020841B1 (en)
ES (3) ES2672095T3 (en)
GB (1) GB0908613D0 (en)
HR (3) HRP20170086T1 (en)
HU (3) HUE038342T2 (en)
LT (3) LT3112377T (en)
MX (1) MX340168B (en)
PL (3) PL2432802T3 (en)
PT (3) PT3112377T (en)
SI (3) SI2432802T1 (en)
SM (3) SMT201800364T1 (en)
TR (2) TR201809945T4 (en)
WO (1) WO2010133828A1 (en)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0908613D0 (en) * 2009-05-20 2009-06-24 Immunocore Ltd T Cell Reseptors
JP6395379B2 (en) 2011-01-18 2018-09-26 バイオニズ リミテッド ライアビリティー カンパニー Compositions and methods for modulating γc cytokine activity
JP6415322B2 (en) 2011-09-15 2018-10-31 アメリカ合衆国 T cell receptor recognizing HLA-A1- or HLA-CW7-restricted MAGE
WO2013048243A1 (en) * 2011-09-29 2013-04-04 Apo-T B.V. Multi-specific binding molecules targeting aberrant cells
US20130273089A1 (en) 2011-11-03 2013-10-17 Tolera Therapeutics, Inc. Antibody and methods for selective inhibition of t-cell responses
CN104870011A (en) 2011-11-03 2015-08-26 托莱拉医疗股份有限公司 Antibody and methods for selective inhibition of T-cell responses
EP3470434A1 (en) 2012-01-13 2019-04-17 Apo-T B.V. Aberrant cell-restricted immunoglobulins provided with a toxic moiety
GB201223172D0 (en) 2012-12-21 2013-02-06 Immunocore Ltd Method
GB201313377D0 (en) * 2013-07-26 2013-09-11 Adaptimmune Ltd T cell receptors
US9959384B2 (en) 2013-12-10 2018-05-01 Bioniz, Llc Methods of developing selective peptide antagonists
KR102290829B1 (en) 2014-03-14 2021-08-18 이뮤노코어 리미티드 Tcr libraries
EP3172325B1 (en) 2014-07-22 2023-06-28 The University of Notre Dame du Lac Molecular constructs and uses thereof
CA2967073A1 (en) 2014-11-07 2016-05-12 Guangzhou Xiangxue Pharmaceutical Co. Ltd Soluble heterodimeric t cell receptor, and preparation method and use thereof
GB201516269D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
GB201516274D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
GB201516275D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
GB201516270D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
GB201516265D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
GB201516277D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR libraries
GB201516272D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
CA3000207A1 (en) 2015-10-09 2017-04-13 Bioniz, Llc Modulating gamma-c-cytokine activity
GB201520557D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520558D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520546D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520595D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520545D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520541D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520565D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520548D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520589D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520575D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201607534D0 (en) 2016-04-29 2016-06-15 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520583D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520562D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520570D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
WO2018083505A1 (en) 2016-11-07 2018-05-11 Immunocore Limited Peptides
GB201520543D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201607535D0 (en) 2016-04-29 2016-06-15 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520597D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520566D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520544D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520559D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520563D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520564D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520568D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd Peptides
GB201520579D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520536D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520539D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520567D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201604468D0 (en) 2016-03-16 2016-04-27 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520542D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
WO2017089786A1 (en) 2015-11-23 2017-06-01 Immunocore Limited Peptides
GB201520603D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520592D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520550D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201522592D0 (en) * 2015-12-22 2016-02-03 Immunocore Ltd T cell receptors
MD3430037T2 (en) * 2016-03-16 2023-01-31 Immatics Biotechnologies Gmbh Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
GB201604953D0 (en) 2016-03-23 2016-05-04 Immunocore Ltd T cell receptors
MY198621A (en) 2016-04-08 2023-09-11 Immunocore Ltd T cell receptors
WO2017192536A1 (en) 2016-05-02 2017-11-09 University Of Kansas Eliminating mhc restriction from the t cell receptor as a strategy for immunotherapy
FI3464380T3 (en) 2016-06-02 2025-01-31 Immunocore Ltd Dosing regimen for gp100-specific tcr - anti-cd3 scfv fusion protein
US20190262400A1 (en) * 2016-10-31 2019-08-29 H. Lee Moffitt Cancer Center And Research Institure, Inc. Artificial antigen presenting cells for expanding immune cells for immunotherapy
CN108203459A (en) * 2016-12-19 2018-06-26 广东香雪精准医疗技术有限公司 Tumour antigen small peptide from PRAME
GB201709866D0 (en) 2017-06-20 2017-08-02 Immunocore Ltd T cell receptors
KR20210010896A (en) 2018-05-14 2021-01-28 이뮤노코어 리미티드 Bifunctional binding polypeptide
GB201815041D0 (en) 2018-09-14 2018-10-31 Scancell Ltd Epitopes
CN113164626A (en) * 2019-01-14 2021-07-23 南京传奇生物科技有限公司 Chimeric receptor polypeptides and uses thereof
HRP20240176T1 (en) 2019-01-17 2024-04-12 Immunocore Limited FORMULATIONS
GB201901305D0 (en) 2019-01-30 2019-03-20 Immunocore Ltd Specific binding molecules
GB201901306D0 (en) 2019-01-30 2019-03-20 Immunocore Ltd Multi-domain binding molecules
JP2022519649A (en) 2019-02-08 2022-03-24 ジェネンテック， インコーポレイテッド How to diagnose and treat cancer
GB201902277D0 (en) 2019-02-19 2019-04-03 King S College London Therapeutic agents
US12006345B2 (en) 2019-02-21 2024-06-11 Xencor, Inc. Untargeted and targeted IL-10 Fc-fusion proteins
CA3134102A1 (en) 2019-03-18 2020-09-24 Ludwig Institute For Cancer Research Ltd A2/ny-eso-1 specific t cell receptors and uses thereof
GB201904328D0 (en) 2019-03-28 2019-05-15 Immunocore Ltd Specific binding molecules
AU2020269255A1 (en) 2019-05-03 2022-01-06 Bioniz Therapeutics, Inc. Modulating the effects of gamma-c-cytokine signaling for the treatment of alopecia and alopecia associated disorders
GB201915282D0 (en) 2019-10-22 2019-12-04 Immunocore Ltd Specific binding molecules
GB202005779D0 (en) 2020-04-21 2020-06-03 Scancell Ltd Anti-tumour immune responses
GB202006629D0 (en) 2020-05-05 2020-06-17 Immunocore Ltd Specific binding molecules
GB202010329D0 (en) 2020-07-06 2020-08-19 Immunocore Ltd Specific binding molecules
WO2022036146A1 (en) 2020-08-12 2022-02-17 Genentech, Inc. Diagnostic and therapeutic methods for cancer
CN112239495B (en) * 2020-10-29 2022-04-12 上海药明生物技术有限公司 Stable TCR structure and applications
WO2022184805A1 (en) 2021-03-03 2022-09-09 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding sars-cov-2 antigenic peptides in complex with a major histocompatibility complex protein
KR20240004937A (en) 2021-05-05 2024-01-11 이매틱스 바이오테크놀로지스 게엠베하 BMA031 antigen-binding polypeptide
EP4113120A1 (en) 2021-06-28 2023-01-04 Immatics Biotechnologies GmbH Method of characterizing the binding characteristics between a peptide of interest and mhc molecules
US20230024554A1 (en) 2021-06-28 2023-01-26 Immatics Biotechnologies Gmbh Method of characterizing the binding characteristics between a peptide of interest and mhc molecules
EP4370540A2 (en) 2021-07-12 2024-05-22 Ludwig Institute for Cancer Research Ltd T cell receptors specific for tumor-associated antigens and methods of use thereof
CN117964777A (en) * 2021-08-26 2024-05-03 瑅安生物医药（杭州）有限公司 Polypeptide fusion molecule close to natural molecule
EP4198052A1 (en) 2021-12-15 2023-06-21 Eberhard Karls Universität Tübingen Medizinische Fakultät Peptides and antigen binding proteins for use in immunotherapy against fibrolamellar hepatocellular carcinoma (fl-hcc) and other cancers
EP4479423A1 (en) 2022-02-20 2024-12-25 Immunocore Limited Hiv-specific binding molecules and tcr
CN120112556A (en) 2022-08-18 2025-06-06 英美偌科有限公司 Multidomain binding molecules
WO2024038183A1 (en) 2022-08-18 2024-02-22 Immunocore Limited Multi-domain binding molecules
TW202413409A (en) 2022-08-18 2024-04-01 英商英美偌科有限公司 Multi-domain binding molecules
KR20250070621A (en) 2022-08-18 2025-05-20 이뮤노코어 리미티드 T cell receptor fusion protein specific for MAGE-A4
WO2024067821A1 (en) * 2022-09-30 2024-04-04 瑅安生物医药（杭州）有限公司 Modified cell and use thereof
AU2023395989A1 (en) 2022-12-16 2025-07-24 Repertoire Immune Medicines, Inc. T cell receptors binding hpv-16 epitopes
KR20250133716A (en) 2023-01-06 2025-09-08 이뮤노코어 리미티드 Binding molecule for PIWIL1 peptide-HLA complex
TW202434640A (en) 2023-01-06 2024-09-01 英商英美偌科有限公司 Binding molecules
US12319747B2 (en) 2023-07-03 2025-06-03 Medicovestor, Inc. Methods of using anti-SP17 immunotherapeutics
US12364777B2 (en) 2023-10-20 2025-07-22 Medicovestor, Inc. Homodimeric antibodies for use in treating cancers and methods of use
TW202530269A (en) * 2023-10-27 2025-08-01 大陸商北京可瑞生物科技有限公司 T cell receptor-based multispecific polypeptide molecules and compostions and uses thereof
GB202320012D0 (en) 2023-12-22 2024-02-07 Immunocore Ltd Bispecific molecules
US12116410B1 (en) 2023-12-26 2024-10-15 Medicovestor, Inc. Methods of manufacturing dimeric antibodies
US12240900B1 (en) 2024-02-02 2025-03-04 Medicovestor, Inc. Nucleic acids, vectors, and cells that encode antibodies and other proteins that bind folate receptor alpha
US12378314B1 (en) 2024-02-02 2025-08-05 Medicovestor, Inc. Proteins that bind folate receptor alpha including fully-human antibodies
US12258396B1 (en) 2024-02-02 2025-03-25 Medicovestor, Inc. Methods of using immunotherapeutics that bind folate receptor alpha
GB202406837D0 (en) 2024-05-14 2024-06-26 Immunocore Ltd Screening methods
GB2641580A (en) 2024-06-07 2025-12-10 T Therapeutics Ltd Tumour-transforming multispecific proteins

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122004000008I1 (en) * 1991-06-14 2005-06-09 Genentech Inc Humanized heregulin antibody.
CA2327314A1 (en) * 1998-05-19 1999-11-25 Avidex Limited Soluble t cell receptor
ATE370967T1 (en) * 1998-10-21 2007-09-15 Altor Bioscience Corp POLYSPECIFIC BINDING MOLECULES AND THEIR USE
JP2004501364A (en) * 2000-05-25 2004-01-15 スノル・モレキュラー・コーポレーション Modulation of T-cell receptor interaction
CN101712721A (en) 2000-06-05 2010-05-26 阿尔托生物科学有限公司 T cell receptor fusions and conjugates and methods of use thereof
US20030017134A1 (en) * 2001-06-19 2003-01-23 Technion Research And Development Foundation Ltd. Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
IL160359A0 (en) 2001-08-31 2004-07-25 Avidex Ltd Soluble t cell receptor
US20030223994A1 (en) 2002-02-20 2003-12-04 Hoogenboom Henricus Renerus Jacobus Mattheus MHC-peptide complex binding ligands
CA2501870C (en) 2002-10-09 2013-07-02 Avidex Limited Single chain recombinant t cell receptors
GB0304068D0 (en) * 2003-02-22 2003-03-26 Avidex Ltd Substances
DK1765860T3 (en) * 2004-05-19 2009-03-09 Immunocore Ltd New-ESO-T. cell receptor with high affinity
US20090042285A1 (en) * 2004-05-27 2009-02-12 Weidanz Jon A Antibodies at T cell receptor mimics, methods of production and uses thereof
AU2005247950B2 (en) 2004-05-27 2012-02-02 Receptor Logic, Inc. Antibodies as T cell receptor mimics, methods of production and uses thereof
WO2005120166A2 (en) 2004-06-09 2005-12-22 Technion Research & Development Foundation Ltd. Antibodies for selective apoptosis of cells
JP2008514685A (en) 2004-10-01 2008-05-08 メディジーン リミテッド T cell receptor containing a non-natural disulfide interchain linkage linked to a therapeutic agent
US20080044413A1 (en) * 2005-12-21 2008-02-21 Hammond Scott A EphA2 BiTE molecules and uses thereof
CN101370827B (en) * 2005-12-21 2015-10-14 麦克罗梅特股份公司 There is the pharmaceutical composition of CEA resistance
GB0708585D0 (en) 2007-05-03 2007-06-13 Queen Mary & Westfield College Novel antibody and use in diagnosis and therapy of arthropathies
GB0816096D0 (en) 2008-09-04 2008-10-15 Medigene Ltd Diabetes t cell receptors
GB0908613D0 (en) 2009-05-20 2009-06-24 Immunocore Ltd T Cell Reseptors
GB0911566D0 (en) * 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors

Also Published As

Publication number Publication date
US20190275165A1 (en) 2019-09-12
EP2432802A1 (en) 2012-03-28
CA2968393A1 (en) 2010-11-25
AU2010250951B2 (en) 2015-04-30
ES2672095T3 (en) 2018-06-12
PT3112376T (en) 2019-05-20
ES2721058T3 (en) 2019-07-26
US10517960B2 (en) 2019-12-31
SI3112377T1 (en) 2018-06-29
CN102439034A (en) 2012-05-02
EP3112376A3 (en) 2017-03-29
LT2432802T (en) 2017-01-10
BRPI1013029A2 (en) 2016-04-05
US10130721B2 (en) 2018-11-20
EP3112376B1 (en) 2019-01-23
HUE043245T2 (en) 2019-08-28
HRP20190674T1 (en) 2019-08-09
EP3112376A2 (en) 2017-01-04
JP2019172678A (en) 2019-10-10
CY1121558T1 (en) 2020-05-29
SI3112376T1 (en) 2019-08-30
EP3112377B1 (en) 2018-04-18
SMT201900232T1 (en) 2019-05-10
ES2608653T3 (en) 2017-04-12
CY1120439T1 (en) 2019-07-10
HRP20180757T1 (en) 2018-07-27
DK3112377T3 (en) 2018-07-30
CA2762604A1 (en) 2010-11-25
EP3112377A1 (en) 2017-01-04
DK3112376T3 (en) 2019-04-29
US20230241238A1 (en) 2023-08-03
TR201809945T4 (en) 2018-08-27
EP2432802B1 (en) 2016-11-02
EA020841B1 (en) 2015-02-27
EA201101660A8 (en) 2014-09-30
JP2012527439A (en) 2012-11-08
DK2432802T3 (en) 2017-02-13
CN102439034B (en) 2015-01-28
HRP20170086T1 (en) 2017-06-02
SMT201700067T1 (en) 2017-05-08
AU2010250951A1 (en) 2011-12-08
LT3112376T (en) 2019-05-10
MX2011012184A (en) 2012-03-26
PL2432802T3 (en) 2017-07-31
WO2010133828A1 (en) 2010-11-25
LT3112377T (en) 2018-05-25
CY1118405T1 (en) 2017-06-28
CA2762604C (en) 2018-01-16
JP5667171B2 (en) 2015-02-12
EA201101660A1 (en) 2012-05-30
TR201905437T4 (en) 2019-05-21
MX340168B (en) 2016-06-29
HUE038342T2 (en) 2018-10-29
US20120190828A1 (en) 2012-07-26
PT3112377T (en) 2018-07-13
CA2968393C (en) 2019-07-23
PL3112376T3 (en) 2019-07-31
SI2432802T1 (en) 2017-01-31
US10420846B2 (en) 2019-09-24
JP2015096527A (en) 2015-05-21
HUE032929T2 (en) 2017-11-28
SMT201800364T1 (en) 2018-09-13
JP2017110019A (en) 2017-06-22
US20190231896A1 (en) 2019-08-01
US10576162B2 (en) 2020-03-03
US20190247512A1 (en) 2019-08-15
US20190231895A1 (en) 2019-08-01
PT2432802T (en) 2017-02-13
PL3112377T3 (en) 2018-10-31

Similar Documents

Publication Publication Date Title
GB0908613D0 (en) T Cell Reseptors
IL216624A0 (en) Fucosylation-deficient cells
EP2457078A4 (en) Nanofluidic cell
ZA201109522B (en) T cell receptors
GB0908910D0 (en) Fuel cell
EP2478584A4 (en) Battery cell
EP2448051A4 (en) Fuel cell
GB201017421D0 (en) Cell
EP2413405A4 (en) Fuel cell
GB0913836D0 (en) Fuel cell
EP2441107A4 (en) Thin battery
GB0920775D0 (en) Cells
GB0913469D0 (en) Cell support
PL2405924T3 (en) Plasma-adapted full electrolyte solution
ZA201201864B (en) Fuel cell
GB0917143D0 (en) Cell stack
ZA201107671B (en) Photovoltaic cell
GB0920035D0 (en) Cell
GB0901675D0 (en) Cells
GB0908223D0 (en) Cells
HUE052153T2 (en) Fucosylation-deficient cells
GB0905615D0 (en) Cell line
TWI372482B (en) Battery
GB2471262B (en) Photovoltaic cell
GB0810505D0 (en) M cell

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)